KRRO News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

KR

Mkt Cap

$125.0M

Volume

96.43K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Korro to Present at the 44th Annual J.P. Morgan Healthcare ConferenceKorro Bio announced that CEO Ram Aiyar will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The biopharmaceutical company is focused on developing RNA editing genetic medicines for rare and prevalent diseases. A live webcast will be available on their investor relations website.GlobeNewswire Inc. · Jan 8, 2026

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin DeficiencyKorro Bio, a clinical-stage biopharmaceutical company, announced that the FDA has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is currently being evaluated in a Phase 1/2a clinical study, and the company expects to report interim data in the second half of 2025.GlobeNewswire Inc. · Mar 14, 2025

4 Biotech Stocks With AI, Machine Learning ProwessThe article discusses four biotech companies leveraging AI and machine learning technology to improve drug discovery and development processes. These companies are Absci, Firefly Neuroscience, Korro Bio, and NeuroSense Therapeutics.Investing.com · Nov 8, 2024

Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both StocksNovo Nordisk and Korro Bio announced a $530 million drug development collaboration, but this is not seen as a threat to Moderna as the companies are working on different approaches to mRNA technology.The Motley Fool · Sep 19, 2024

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International ConferenceCAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD.GlobeNewswire Inc. · May 20, 2024

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerOn track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024GlobeNewswire Inc. · May 14, 2024

Korro Announces $70 Million Private PlacementCAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement (PIPE) that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses. The PIPE is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions.GlobeNewswire Inc. · Apr 18, 2024

Korro to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will participate, present, and meet investors regarding progress of KRRO-110, Korro’s best-in-class candidate for AATD, at the following upcoming investor conferences:GlobeNewswire Inc. · Apr 1, 2024

Korro Reports Full Year 2023 Financial Results and Highlights Recent ProgressCAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, today reported financial results for the full year ended December 31, 2023, and reiterated its recent progress and anticipated milestones.GlobeNewswire Inc. · Mar 26, 2024

Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 86.9% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.Zacks Investment Research · Feb 27, 2024

KR

KRROKorro Bio, Inc. Common Stock

KRRO

Pay with—

Available Balance0.00

Your PositionYou don't own any KRRO yet.

Related Tickers

Earnings